All roads lead to targeted diffuse large B-cell lymphoma approaches

Peng-Peng Xu; Yu-Jia Huo; Wei-Li Zhao

doi:10.1016/j.ccell.2022.01.013

All roads lead to targeted diffuse large B-cell lymphoma approaches

Cancer Cell. 2022 Feb 14;40(2):131-133. doi: 10.1016/j.ccell.2022.01.013.

Authors

Peng-Peng Xu¹, Yu-Jia Huo¹, Wei-Li Zhao²

Affiliations

¹ Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
² Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China. Electronic address: zhao.weili@yahoo.com.

PMID: 35167823
DOI: 10.1016/j.ccell.2022.01.013

Abstract

Two recent reports in the New England Journal of Medicine highlight the successful application of novel targeted therapies to improve the clinical outcomes of diffuse large B-cell lymphoma (DLBCL). These findings encourage us to pursue further mechanism-based therapeutic uses to make DLBCL curable in the era of precision medicine.

Publication types

Comment

MeSH terms

Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / genetics
Lymphoma, Large B-Cell, Diffuse* / pathology
Molecular Targeted Therapy
Precision Medicine